Ernexa Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ernexa Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 2,198% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-101.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 82% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-32.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 65% of Healthcare companies in United States.
Cash Cushion Ratio
+41%Cash, after subtracting all debt, equals 41% of its market value (net cash).
Higher than 75% of Healthcare companies in United States.
Tangible Assets Ratio
65%Of every $100 the company owns, $65 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 66% of Healthcare companies in United States.
Tangible Net Worth Ratio
15%Of every $100 of net worth, $15 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 67% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Ernexa Therapeutics Inc. made a loss over the last year. Ernexa Therapeutics Inc. owes $0.49 for every $1 it owns. Ernexa Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossErnexa Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.06The share price is 1.06 times Ernexa Therapeutics Inc.'s book value per share, lower than 78% of Healthcare companies in United States.
Market cap
$3 MThe total market value of all of Ernexa Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 95% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$3 MWhat Ernexa Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.96Net worth divided by the number of shares. The share price of $2.08 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
-320.7%Ernexa Therapeutics Inc. lost 320.7% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
Owes vs Owns
0.49×Ernexa Therapeutics Inc. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Dividend yield
NoneErnexa Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossErnexa Therapeutics Inc. made a loss in each of the last two years.
Interest cover
Not coveredErnexa Therapeutics Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashErnexa Therapeutics Inc. held $1 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ernexa Therapeutics Inc.: $3 M ÷ $3 M (30 Jun 2026) = 1.1.
What is Ernexa Therapeutics Inc.'s return on equity?
Ernexa Therapeutics Inc. lost 320.7% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
How much does Ernexa Therapeutics Inc. owe compared with what it owns?
Ernexa Therapeutics Inc. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Does Ernexa Therapeutics Inc. pay a dividend?
No. Ernexa Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.